UBS Maintains Neutral on Amgen, Lowers Price Target to $326
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow maintains a Neutral rating on Amgen (NASDAQ:AMGN) and lowers the price target from $335 to $326.

October 31, 2024 | 7:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS analyst Colin Bristow maintains a Neutral rating on Amgen and lowers the price target from $335 to $326, indicating a slightly less optimistic outlook.
The lowering of the price target by UBS suggests a slightly less optimistic view on Amgen's stock performance, which could lead to a short-term negative impact on the stock price. The Neutral rating indicates no strong buy or sell recommendation, but the reduced price target may influence investor sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100